Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission

Pierre Quartier; Ekaterina Alexeeva; Carine Wouters; Inmaculada Calvo; Tilmann Kallinich; Bo Magnusson; Nico Wulffraat; Xiaoling Wei; Alan Slade; Ken Abrams; Alberto Martini

Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission

Pierre Quartier, Ekaterina Alexeeva, Carine Wouters, Inmaculada Calvo, Tilmann Kallinich, Bo Magnusson, Nico Wulffraat, Xiaoling Wei, Alan Slade, Ken Abrams, Alberto Martini

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Arthritis & Rheumatology
Volume	70
Publication status	Published - Sept 2018

Cite this

Quartier, P., Alexeeva, E., Wouters, C., Calvo, I., Kallinich, T., Magnusson, B., Wulffraat, N., Wei, X., Slade, A., Abrams, K., & Martini, A. (2018). Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission. Arthritis & Rheumatology, 70.

@article{7d3eb5510dcd4876a39a1e216193b34f,

title = "Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission",

author = "Pierre Quartier and Ekaterina Alexeeva and Carine Wouters and Inmaculada Calvo and Tilmann Kallinich and Bo Magnusson and Nico Wulffraat and Xiaoling Wei and Alan Slade and Ken Abrams and Alberto Martini",

year = "2018",

month = sep,

language = "English",

volume = "70",

journal = "Arthritis \& Rheumatology",

issn = "2326-5191",

publisher = "John Wiley \& Sons Inc.",

}

Quartier, P, Alexeeva, E, Wouters, C, Calvo, I, Kallinich, T, Magnusson, B, Wulffraat, N, Wei, X, Slade, A, Abrams, K & Martini, A 2018, 'Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission', Arthritis & Rheumatology, vol. 70.

Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission. / Quartier, Pierre; Alexeeva, Ekaterina; Wouters, Carine et al.
In: Arthritis & Rheumatology, Vol. 70, 09.2018.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission

AU - Quartier, Pierre

AU - Alexeeva, Ekaterina

AU - Wouters, Carine

AU - Calvo, Inmaculada

AU - Kallinich, Tilmann

AU - Magnusson, Bo

AU - Wulffraat, Nico

AU - Wei, Xiaoling

AU - Slade, Alan

AU - Abrams, Ken

AU - Martini, Alberto

PY - 2018/9

Y1 - 2018/9

M3 - Meeting Abstract

SN - 2326-5191

VL - 70

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

ER -